# Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 14.7 | 122.5 | (72.6-193.7) |  | Male | 14 | 10.1 | 138.3 | (75.5-232.0) |
| Female | 7 | 5.5 | 128.3 | (51.4-264.4) |  | Female | 13 | 8.6 | 151.6 | (80.6-259.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 9 | 8.9 | 100.7 | (45.9-191.1) |
| Female | 63 | 65.3 | 96.5 | (74.2-123.5) |  | Female | 5 | 7.6 | 65.5 | (21.1-152.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 7.5 | 80.1 | (29.2-174.3) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 17.0 | 123.7 | (76.5-189.1) |  |  |  |  |  |  |
| Female | 21 | 16.9 | 124.3 | (76.9-190.0) |  | Female | 8 | 5.9 | 135.9 | (58.5-267.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  | Male | 4 | 5.2 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 3 | 5.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 61 | 57.2 | 106.6 | (81.5-136.9) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 8.8 | 228.6 | (139.5-353.0) |  | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 8 | 5.0 | 158.8 | (68.4-312.9) |  | Female | 4 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 6 | 0.8 | 767.0 | (280.1-1669.4) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 6.1 | nc | (nc-nc) |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 8 | 4.6 | 175.2 | (75.4-345.3) |  | Female | 21 | 13.1 | 160.4 | (99.2-245.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 5.4 | 111.4 | (40.7-242.5) |  |  |  |  |  |  |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 18 | 14.8 | 121.3 | (71.9-191.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 46 | 27.1 | 169.7 | (124.3-226.4) |  | Male | 250 | 208.0 | 120.2 | (105.8-136.1) |
| Female | 43 | 29.0 | 148.1 | (107.2-199.5) |  | Female | 258 | 215.4 | 119.8 | (105.6-135.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

10

# Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 20.3 | 103.5 | (64.0-158.2) |  | Male | 13 | 14.2 | 91.8 | (48.8-157.0) |
| Female | 7 | 7.0 | 99.6 | (39.9-205.2) |  | Female | 17 | 11.3 | 150.1 | (87.4-240.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 4.4 | 183.3 | (78.9-361.1) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 1 | 3.5 | nc | (nc-nc) |  | Female | 5 | 3.1 | 161.3 | (52.0-376.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 14 | 12.5 | 111.9 | (61.1-187.8) |
| Female | 102 | 90.3 | 112.9 | (92.1-137.1) |  | Female | 14 | 10.1 | 139.3 | (76.1-233.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 10.8 | 92.9 | (44.5-170.8) |
| Female | 3 | 3.3 | nc | (nc-nc) |  | Female | 5 | 4.3 | 115.5 | (37.2-269.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 24.0 | 83.4 | (50.9-128.8) |  |  |  |  |  |  |
| Female | 22 | 22.1 | 99.4 | (62.3-150.5) |  | Female | 14 | 8.0 | 176.0 | (96.1-295.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 5.8 | 85.5 | (27.6-199.6) |  | Male | 10 | 7.2 | 139.3 | (66.7-256.1) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 4 | 6.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 81 | 79.7 | 101.6 | (80.7-126.3) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 12.4 | 88.7 | (44.2-158.8) |  | Male | 1 | 5.0 | nc | (nc-nc) |
| Female | 5 | 6.8 | 73.9 | (23.8-172.5) |  | Female | 4 | 2.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 8.6 | 105.2 | (48.0-199.7) |  | Male | 5 | 6.0 | 83.8 | (27.0-195.6) |
| Female | 11 | 6.0 | 183.6 | (91.5-328.5) |  | Female | 14 | 17.7 | 78.9 | (43.1-132.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 7.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 19 | 20.2 | 93.8 | (56.5-146.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 37.8 | 50.3 | (30.3-78.6) |  | Male | 250 | 290.2 | 86.1 | (75.8-97.5) |
| Female | 26 | 37.9 | 68.5 | (44.8-100.4) |  | Female | 299 | 288.7 | 103.6 | (92.1-116.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

11

# Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 12.5 | 160.5 | (98.0-247.9) |  | Male | 8 | 8.0 | 99.6 | (42.9-196.3) |
| Female | 5 | 4.4 | 112.7 | (36.3-263.1) |  | Female | 5 | 6.2 | 80.9 | (26.1-188.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 2.3 | 310.4 | (124.4-639.6) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 4 | 1.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 11 | 7.1 | 155.0 | (77.3-277.3) |
| Female | 44 | 48.0 | 91.6 | (66.6-123.0) |  | Female | 6 | 5.9 | 101.6 | (37.1-221.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 5.7 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 15 | 13.7 | 109.5 | (61.2-180.6) |  |  |  |  |  |  |
| Female | 10 | 13.5 | 74.0 | (35.4-136.1) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  | Male | 8 | 4.2 | 189.2 | (81.5-372.8) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 0.9 | nc | (nc-nc) |  | Male | 55 | 45.2 | 121.8 | (91.7-158.5) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 6.8 | 133.3 | (60.8-253.0) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.8 | nc | (nc-nc) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 6 | 3.5 | 173.1 | (63.2-376.8) |  | Female | 11 | 8.6 | 127.7 | (63.7-228.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 11 | 10.9 | 100.5 | (50.1-179.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 22.6 | 150.2 | (104.0-209.9) |  | Male | 197 | 166.0 | 118.7 | (102.7-136.4) |
| Female | 22 | 23.0 | 95.5 | (59.8-144.5) |  | Female | 152 | 162.7 | 93.5 | (79.2-109.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

12

# Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 11.6 | 86.1 | (41.2-158.3) |  | Male | 5 | 7.1 | 70.5 | (22.7-164.4) |
| Female | 6 | 4.4 | 137.2 | (50.1-298.6) |  | Female | 4 | 5.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 6 | 2.1 | 282.3 | (103.1-614.4) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 7 | 6.3 | 111.4 | (44.6-229.6) |
| Female | 34 | 42.3 | 80.4 | (55.7-112.3) |  | Female | 9 | 5.6 | 162.0 | (73.9-307.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.8 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 0 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 12.3 | 89.4 | (44.6-159.9) |  |  |  |  |  |  |
| Female | 12 | 13.2 | 91.1 | (47.0-159.1) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 5 | 4.3 | 116.2 | (37.4-271.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 45 | 38.5 | 116.8 | (85.2-156.3) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 5.7 | nc | (nc-nc) |  | Male | 0 | 2.6 | nc | (nc-nc) |
| Female | 3 | 3.5 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 4.4 | nc | (nc-nc) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 5 | 7.1 | 70.5 | (22.7-164.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 7 | 9.7 | 72.5 | (29.0-149.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 20.6 | 87.6 | (51.9-138.4) |  | Male | 134 | 146.3 | 91.6 | (76.7-108.5) |
| Female | 36 | 21.9 | 164.6 | (115.3-227.9) |  | Female | 144 | 149.2 | 96.5 | (81.4-113.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

13

# Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 36 | 36.6 | 98.5 | (68.9-136.3) |  | Male | 20 | 22.7 | 88.0 | (53.8-136.0) |
| Female | 13 | 14.7 | 88.5 | (47.1-151.3) |  | Female | 14 | 18.6 | 75.2 | (41.1-126.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 6.2 | 80.3 | (25.9-187.5) |  | Male | 5 | 6.7 | 74.3 | (23.9-173.3) |
| Female | 3 | 5.7 | nc | (nc-nc) |  | Female | 4 | 6.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 24 | 20.1 | 119.2 | (76.4-177.4) |
| Female | 156 | 142.4 | 109.5 | (93.0-128.1) |  | Female | 17 | 18.7 | 91.0 | (53.0-145.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 24 | 15.7 | 152.8 | (97.9-227.4) |
| Female | 7 | 4.6 | 151.6 | (60.7-312.4) |  | Female | 9 | 7.6 | 118.0 | (53.8-224.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 42 | 39.6 | 106.1 | (76.5-143.5) |  |  |  |  |  |  |
| Female | 45 | 44.6 | 100.8 | (73.5-134.9) |  | Female | 11 | 13.3 | 83.0 | (41.4-148.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 9.4 | 63.8 | (23.3-138.9) |  | Male | 12 | 12.3 | 97.9 | (50.5-171.1) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 12 | 14.5 | 82.5 | (42.6-144.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  | Male | 110 | 123.5 | 89.1 | (73.2-107.4) |
| Female | 4 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 18.5 | 118.9 | (74.5-180.1) |  | Male | 12 | 8.4 | 143.1 | (73.8-249.9) |
| Female | 8 | 11.7 | 68.6 | (29.5-135.2) |  | Female | 5 | 5.7 | 87.6 | (28.2-204.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 5.1 | 116.6 | (42.6-253.9) |  | Male | 2 | 3.9 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 14.0 | 64.4 | (29.4-122.2) |  | Male | 7 | 8.1 | 86.1 | (34.5-177.5) |
| Female | 9 | 11.2 | 80.6 | (36.8-153.1) |  | Female | 19 | 23.9 | 79.6 | (47.9-124.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 11.7 | 59.7 | (23.9-123.0) |  |  |  |  |  |  |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 25 | 32.4 | 77.2 | (50.0-114.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 81 | 64.6 | 125.4 | (99.6-155.9) |  | Male | 461 | 467.6 | 98.6 | (89.8-108.0) |
| Female | 77 | 72.1 | 106.8 | (84.2-133.4) |  | Female | 479 | 501.2 | 95.6 | (87.2-104.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

14

# Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 2 | 3.9 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 2 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 3 | 13.3 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 8 | 10.7 | 74.9 | (32.2-147.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

15

# Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 15.4 | 149.1 | (94.5-223.8) |  | Male | 14 | 10.6 | 132.1 | (72.2-221.7) |
| Female | 10 | 6.2 | 161.9 | (77.5-297.8) |  | Female | 9 | 9.3 | 96.9 | (44.2-184.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 5 | 3.1 | 163.5 | (52.7-381.5) |
| Female | 6 | 2.8 | 212.6 | (77.6-462.7) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 10 | 9.3 | 107.0 | (51.2-196.8) |
| Female | 81 | 71.2 | 113.8 | (90.4-141.5) |  | Female | 11 | 8.4 | 130.3 | (64.9-233.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 7.8 | 178.8 | (97.7-300.0) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 5 | 3.6 | 140.1 | (45.2-327.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 17.8 | 123.5 | (77.4-187.0) |  |  |  |  |  |  |
| Female | 29 | 19.3 | 150.2 | (100.6-215.7) |  | Female | 8 | 6.4 | 124.4 | (53.6-245.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 4.3 | 230.9 | (110.5-424.6) |  | Male | 10 | 5.4 | 186.0 | (89.1-342.1) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 7 | 6.0 | 116.2 | (46.6-239.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 58 | 58.7 | 98.8 | (75.1-127.8) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 9.1 | nc | (nc-nc) |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 3 | 5.5 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 6.4 | 140.5 | (64.1-266.7) |  | Male | 1 | 4.4 | nc | (nc-nc) |
| Female | 5 | 5.1 | 98.6 | (31.8-230.1) |  | Female | 13 | 13.8 | 94.1 | (50.0-160.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 5.7 | 87.9 | (28.3-205.1) |  |  |  |  |  |  |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 13 | 16.0 | 81.1 | (43.2-138.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 30 | 28.4 | 105.7 | (71.3-151.0) |  | Male | 243 | 216.1 | 112.4 | (98.7-127.5) |
| Female | 44 | 31.9 | 137.9 | (100.2-185.1) |  | Female | 273 | 236.8 | 115.3 | (102.0-129.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

16

# Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 20.6 | 68.0 | (37.1-114.1) |  | Male | 8 | 13.7 | 58.5 | (25.2-115.2) |
| Female | 2 | 8.0 | nc | (nc-nc) |  | Female | 14 | 13.4 | 104.5 | (57.1-175.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.8 | nc | (nc-nc) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 2 | 4.5 | nc | (nc-nc) |  | Female | 0 | 3.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 8 | 12.8 | 62.3 | (26.8-122.7) |
| Female | 75 | 83.0 | 90.4 | (71.1-113.3) |  | Female | 14 | 11.2 | 125.5 | (68.5-210.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 9.3 | 107.7 | (51.5-198.0) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 2 | 4.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 22.2 | 76.7 | (44.7-122.9) |  |  |  |  |  |  |
| Female | 19 | 24.5 | 77.4 | (46.6-120.9) |  | Female | 12 | 8.5 | 141.1 | (72.8-246.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.4 | nc | (nc-nc) |  | Male | 5 | 6.9 | 72.5 | (23.4-169.2) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 5 | 7.9 | 63.3 | (20.4-147.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 3.8 | nc | (nc-nc) |  | Male | 66 | 71.7 | 92.0 | (71.1-117.0) |
| Female | 1 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 10.7 | 55.9 | (20.4-121.7) |  | Male | 1 | 4.7 | nc | (nc-nc) |
| Female | 5 | 6.8 | 73.5 | (23.7-171.5) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  | Male | 2 | 6.6 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 9.6 | 93.9 | (42.8-178.2) |  | Male | 5 | 6.2 | 81.3 | (26.2-189.7) |
| Female | 5 | 7.3 | 68.5 | (22.1-160.0) |  | Female | 5 | 20.6 | 24.2 | (7.8-56.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 6.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.4 | nc | (nc-nc) |  | Female | 14 | 19.3 | 72.6 | (39.6-121.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 36.8 | 40.7 | (22.8-67.2) |  | Male | 199 | 283.0 | 70.3 | (60.9-80.8) |
| Female | 20 | 40.9 | 48.9 | (29.9-75.5) |  | Female | 221 | 303.7 | 72.8 | (63.5-83.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

17

# Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 26 | 34.1 | 76.1 | (49.7-111.6) |  | Male | 21 | 22.8 | 92.2 | (57.1-141.0) |
| Female | 13 | 12.9 | 100.8 | (53.6-172.4) |  | Female | 24 | 18.6 | 128.9 | (82.6-191.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 6.7 | 88.9 | (32.5-193.6) |  | Male | 8 | 6.7 | 119.6 | (51.5-235.7) |
| Female | 5 | 5.8 | 86.2 | (27.8-201.2) |  | Female | 6 | 5.5 | 108.6 | (39.7-236.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 25 | 20.1 | 124.4 | (80.5-183.7) |
| Female | 144 | 145.7 | 98.8 | (83.4-116.4) |  | Female | 17 | 17.4 | 97.6 | (56.8-156.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 24 | 16.8 | 142.8 | (91.5-212.5) |
| Female | 2 | 5.1 | nc | (nc-nc) |  | Female | 5 | 7.3 | 68.3 | (22.0-159.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 28 | 38.8 | 72.1 | (47.9-104.2) |  |  |  |  |  |  |
| Female | 33 | 40.1 | 82.4 | (56.7-115.7) |  | Female | 17 | 13.2 | 129.2 | (75.2-206.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 9.5 | 73.6 | (29.5-151.7) |  | Male | 12 | 11.9 | 101.2 | (52.3-176.9) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 11 | 12.6 | 87.3 | (43.5-156.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 127 | 128.8 | 98.6 | (82.2-117.3) |
| Female | 3 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 19.5 | 61.5 | (31.7-107.4) |  | Male | 10 | 8.1 | 122.7 | (58.7-225.7) |
| Female | 10 | 11.4 | 88.0 | (42.1-161.8) |  | Female | 4 | 5.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 5.3 | nc | (nc-nc) |  | Male | 6 | 4.2 | 141.7 | (51.7-308.4) |
| Female | 2 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 13.8 | 144.5 | (88.2-223.2) |  | Male | 15 | 9.0 | 166.5 | (93.1-274.7) |
| Female | 13 | 10.5 | 124.2 | (66.1-212.5) |  | Female | 34 | 26.9 | 126.5 | (87.6-176.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 12.3 | 81.2 | (38.9-149.3) |  |  |  |  |  |  |
| Female | 2 | 3.9 | nc | (nc-nc) |  | Female | 28 | 32.7 | 85.6 | (56.9-123.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 37 | 62.9 | 58.8 | (41.4-81.1) |  | Male | 432 | 470.4 | 91.8 | (83.4-100.9) |
| Female | 41 | 66.6 | 61.6 | (44.2-83.6) |  | Female | 451 | 485.9 | 92.8 | (84.5-101.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

18

# Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 3 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 4.6 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

19

# Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 44 | 47.8 | 92.1 | (66.9-123.6) |  | Male | 32 | 30.7 | 104.3 | (71.4-147.3) |
| Female | 20 | 19.7 | 101.4 | (61.9-156.7) |  | Female | 28 | 27.1 | 103.4 | (68.7-149.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 8.7 | nc | (nc-nc) |  | Male | 12 | 9.0 | 134.1 | (69.2-234.2) |
| Female | 8 | 8.3 | 96.9 | (41.7-191.0) |  | Female | 8 | 8.3 | 96.6 | (41.6-190.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 21 | 27.0 | 77.7 | (48.1-118.7) |
| Female | 234 | 204.2 | 114.6 | (100.4-130.2) |  | Female | 29 | 25.8 | 112.3 | (75.2-161.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 21.0 | 66.8 | (36.5-112.1) |
| Female | 1 | 7.3 | nc | (nc-nc) |  | Female | 17 | 10.6 | 160.2 | (93.3-256.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 44 | 52.2 | 84.3 | (61.2-113.2) |  |  |  |  |  |  |
| Female | 54 | 60.3 | 89.6 | (67.3-116.9) |  | Female | 20 | 18.7 | 107.0 | (65.3-165.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 15 | 12.3 | 121.6 | (68.0-200.5) |  | Male | 12 | 16.0 | 75.0 | (38.7-131.0) |
| Female | 1 | 3.8 | nc | (nc-nc) |  | Female | 19 | 19.3 | 98.2 | (59.1-153.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 154 | 160.3 | 96.1 | (81.5-112.5) |
| Female | 5 | 3.2 | 156.9 | (50.6-366.3) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 24 | 25.1 | 95.7 | (61.3-142.4) |  | Male | 10 | 11.1 | 90.5 | (43.3-166.4) |
| Female | 14 | 16.5 | 84.8 | (46.3-142.3) |  | Female | 5 | 7.6 | 65.7 | (21.2-153.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 6.8 | nc | (nc-nc) |  | Male | 7 | 6.2 | 112.5 | (45.1-231.8) |
| Female | 2 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 18.8 | 85.2 | (48.7-138.4) |  | Male | 12 | 11.5 | 104.1 | (53.7-181.8) |
| Female | 13 | 15.6 | 83.4 | (44.4-142.6) |  | Female | 36 | 37.8 | 95.2 | (66.6-131.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 18 | 15.5 | 115.8 | (68.6-183.1) |  |  |  |  |  |  |
| Female | 3 | 5.8 | nc | (nc-nc) |  | Female | 41 | 45.8 | 89.6 | (64.3-121.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 71 | 85.0 | 83.5 | (65.2-105.3) |  | Male | 557 | 618.8 | 90.0 | (82.7-97.8) |
| Female | 77 | 99.6 | 77.3 | (61.0-96.6) |  | Female | 695 | 705.5 | 98.5 | (91.3-106.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

20

# Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 5.7 | 157.1 | (71.7-298.3) |  | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 20 | 23.0 | 86.8 | (53.0-134.0) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 6.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 5.4 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 22 | 23.6 | 93.2 | (58.4-141.1) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 2.4 | 205.4 | (66.2-479.4) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 4 | 4.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 5 | 5.2 | 95.4 | (30.7-222.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 10.8 | 55.7 | (20.3-121.2) |  | Male | 67 | 83.9 | 79.8 | (61.9-101.4) |
| Female | 8 | 9.3 | 85.9 | (37.0-169.3) |  | Female | 66 | 72.9 | 90.5 | (70.0-115.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

21

# Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 5 | 2.2 | 231.8 | (74.7-541.0) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 3 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 3 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 13 | 12.2 | 106.3 | (56.5-181.7) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 3.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 4 | 1.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 9 | 12.5 | 71.9 | (32.8-136.4) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.3 | nc | (nc-nc) |  | Female | 5 | 2.8 | 180.2 | (58.1-420.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 5.7 | nc | (nc-nc) |  | Male | 40 | 44.5 | 89.9 | (64.2-122.4) |
| Female | 5 | 5.1 | 98.4 | (31.7-229.7) |  | Female | 50 | 39.0 | 128.1 | (95.1-168.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

22

# Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 1.3 | nc | (nc-nc) |
| Female | 13 | 9.1 | 143.5 | (76.4-245.5) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 7 | 9.3 | 75.3 | (30.2-155.1) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 2 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 4.3 | nc | (nc-nc) |  | Male | 22 | 32.1 | 68.6 | (43.0-103.9) |
| Female | 1 | 4.1 | nc | (nc-nc) |  | Female | 26 | 29.6 | 87.7 | (57.3-128.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

23

# Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 14.9 | 100.7 | (56.3-166.1) |  | Male | 6 | 10.4 | 57.5 | (21.0-125.2) |
| Female | 4 | 5.4 | nc | (nc-nc) |  | Female | 5 | 8.8 | 57.1 | (18.4-133.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 3.2 | nc | (nc-nc) |  | Male | 6 | 3.0 | 200.5 | (73.2-436.4) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 10 | 9.2 | 108.9 | (52.1-200.3) |
| Female | 66 | 67.6 | 97.7 | (75.6-124.3) |  | Female | 4 | 7.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 7.8 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 17.5 | 57.2 | (27.4-105.3) |  |  |  |  |  |  |
| Female | 20 | 16.8 | 119.3 | (72.8-184.2) |  | Female | 10 | 6.0 | 166.0 | (79.5-305.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 4.2 | 188.5 | (81.2-371.5) |  | Male | 6 | 5.2 | 114.4 | (41.8-249.1) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 6 | 5.2 | 116.3 | (42.5-253.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 48 | 57.7 | 83.1 | (61.3-110.2) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 9.0 | 99.5 | (45.4-189.0) |  | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 3 | 5.1 | nc | (nc-nc) |  | Female | 4 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 6.3 | nc | (nc-nc) |  | Male | 5 | 4.4 | 112.6 | (36.3-262.7) |
| Female | 8 | 4.6 | 173.5 | (74.7-341.9) |  | Female | 23 | 13.8 | 166.7 | (105.6-250.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 1.7 | nc | (nc-nc) |  | Female | 16 | 15.3 | 104.2 | (59.5-169.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 27 | 27.5 | 98.1 | (64.6-142.7) |  | Male | 179 | 212.2 | 84.4 | (72.5-97.7) |
| Female | 39 | 29.0 | 134.6 | (95.7-183.9) |  | Female | 237 | 219.1 | 108.1 | (94.8-122.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

24

# Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 13.2 | 128.8 | (75.0-206.3) |  | Male | 6 | 8.4 | 71.1 | (26.0-154.8) |
| Female | 4 | 4.9 | nc | (nc-nc) |  | Female | 4 | 6.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 0 | 2.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 4 | 7.5 | nc | (nc-nc) |
| Female | 35 | 50.2 | 69.7 | (48.5-96.9) |  | Female | 4 | 6.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 5.9 | 170.0 | (81.4-312.7) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 4 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 14.5 | 131.4 | (79.1-205.2) |  |  |  |  |  |  |
| Female | 12 | 15.1 | 79.5 | (41.0-138.8) |  | Female | 7 | 4.7 | 150.4 | (60.3-309.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 3.5 | 173.3 | (63.3-377.3) |  | Male | 5 | 4.5 | 112.2 | (36.2-261.9) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 5 | 4.8 | 103.3 | (33.3-241.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.0 | nc | (nc-nc) |  | Male | 32 | 45.9 | 69.8 | (47.7-98.5) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 7.0 | 129.4 | (59.0-245.7) |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 5 | 4.1 | 123.1 | (39.7-287.2) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.2 | nc | (nc-nc) |  | Male | 0 | 3.2 | nc | (nc-nc) |
| Female | 5 | 3.9 | 128.6 | (41.4-300.1) |  | Female | 12 | 9.1 | 131.3 | (67.8-229.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.4 | 114.2 | (36.8-266.6) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 23 | 11.3 | 203.2 | (128.8-304.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 38 | 23.6 | 160.7 | (113.7-220.6) |  | Male | 178 | 173.0 | 102.9 | (88.3-119.2) |
| Female | 28 | 24.5 | 114.4 | (76.0-165.3) |  | Female | 166 | 174.4 | 95.2 | (81.3-110.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

25

# Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 43 | 42.5 | 101.2 | (73.2-136.3) |  | Male | 28 | 28.6 | 98.0 | (65.1-141.7) |
| Female | 15 | 16.0 | 93.7 | (52.4-154.5) |  | Female | 17 | 23.7 | 71.8 | (41.8-114.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 8.6 | 128.6 | (64.1-230.1) |  | Male | 5 | 8.2 | 60.7 | (19.6-141.7) |
| Female | 7 | 7.3 | 95.6 | (38.3-197.0) |  | Female | 6 | 6.8 | 87.8 | (32.1-191.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 16 | 25.3 | 63.3 | (36.2-102.9) |
| Female | 175 | 177.8 | 98.4 | (84.4-114.1) |  | Female | 19 | 21.7 | 87.6 | (52.7-136.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 24 | 20.4 | 117.9 | (75.5-175.5) |
| Female | 7 | 6.5 | 107.6 | (43.1-221.7) |  | Female | 10 | 9.0 | 110.7 | (53.0-203.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 50 | 48.2 | 103.8 | (77.0-136.8) |  |  |  |  |  |  |
| Female | 40 | 49.6 | 80.7 | (57.6-109.9) |  | Female | 31 | 16.2 | 191.6 | (130.1-271.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 11.5 | 87.0 | (41.7-160.1) |  | Male | 17 | 14.5 | 116.9 | (68.1-187.2) |
| Female | 5 | 3.1 | 163.3 | (52.6-381.2) |  | Female | 16 | 15.6 | 102.3 | (58.5-166.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 9 | 3.8 | 236.6 | (108.0-449.2) |  | Male | 143 | 152.6 | 93.7 | (79.0-110.4) |
| Female | 1 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 18 | 24.0 | 74.9 | (44.4-118.5) |  | Male | 7 | 10.1 | 69.3 | (27.8-142.9) |
| Female | 12 | 14.1 | 85.4 | (44.1-149.2) |  | Female | 7 | 6.2 | 112.4 | (45.0-231.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 6.4 | 78.3 | (25.2-182.6) |  | Male | 6 | 6.7 | 89.5 | (32.7-194.8) |
| Female | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 17.5 | 45.8 | (19.7-90.3) |  | Male | 11 | 11.6 | 94.8 | (47.2-169.6) |
| Female | 10 | 13.2 | 75.7 | (36.2-139.2) |  | Female | 24 | 35.0 | 68.6 | (44.0-102.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 14.8 | 81.0 | (41.8-141.5) |  |  |  |  |  |  |
| Female | 10 | 4.8 | 207.0 | (99.1-380.8) |  | Female | 43 | 39.8 | 108.2 | (78.3-145.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 101 | 76.9 | 131.3 | (106.9-159.5) |  | Male | 563 | 577.7 | 97.5 | (89.6-105.8) |
| Female | 90 | 82.5 | 109.1 | (87.7-134.1) |  | Female | 593 | 602.0 | 98.5 | (90.7-106.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

26

# Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 22.3 | 98.5 | (61.7-149.1) |  | Male | 10 | 13.6 | 73.7 | (35.3-135.5) |
| Female | 9 | 7.9 | 114.1 | (52.0-216.5) |  | Female | 6 | 10.3 | 58.4 | (21.3-127.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.7 | nc | (nc-nc) |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 8 | 3.3 | 242.8 | (104.5-478.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 10 | 12.0 | 83.1 | (39.8-152.8) |
| Female | 77 | 78.7 | 97.9 | (77.2-122.3) |  | Female | 13 | 10.1 | 128.1 | (68.1-219.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 9.1 | 143.6 | (76.4-245.6) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 2 | 4.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 19 | 23.6 | 80.4 | (48.4-125.5) |  |  |  |  |  |  |
| Female | 24 | 23.9 | 100.6 | (64.5-149.7) |  | Female | 8 | 7.3 | 110.2 | (47.5-217.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 5.6 | 89.7 | (28.9-209.3) |  | Male | 6 | 7.4 | 81.6 | (29.8-177.6) |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 7 | 7.7 | 90.3 | (36.2-186.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 55 | 71.8 | 76.6 | (57.7-99.7) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 10.8 | 119.8 | (63.7-204.9) |  | Male | 4 | 5.0 | nc | (nc-nc) |
| Female | 6 | 6.4 | 93.4 | (34.1-203.3) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 3.0 | 197.4 | (72.1-429.6) |  | Male | 4 | 2.2 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 8.4 | 119.0 | (57.0-218.9) |  | Male | 3 | 4.7 | nc | (nc-nc) |
| Female | 5 | 6.0 | 82.7 | (26.7-193.1) |  | Female | 15 | 13.6 | 110.6 | (61.9-182.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 6.8 | 102.4 | (41.0-211.0) |  |  |  |  |  |  |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 18 | 17.8 | 101.0 | (59.8-159.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 39.2 | 71.5 | (47.5-103.3) |  | Male | 239 | 277.8 | 86.0 | (75.5-97.7) |
| Female | 45 | 39.7 | 113.3 | (82.6-151.6) |  | Female | 277 | 274.4 | 100.9 | (89.4-113.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

27

# Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 5.4 | 130.0 | (52.1-267.8) |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 25 | 21.3 | 117.3 | (75.9-173.2) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 5.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 6.2 | nc | (nc-nc) |  | Female | 4 | 1.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.4 | nc | (nc-nc) |  | Male | 8 | 18.4 | 43.4 | (18.7-85.6) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 2.8 | 213.6 | (78.0-465.0) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 5 | 3.7 | 136.4 | (43.9-318.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 4.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 9.7 | 165.7 | (94.7-269.1) |  | Male | 77 | 69.8 | 110.3 | (87.0-137.8) |
| Female | 14 | 10.8 | 129.7 | (70.8-217.6) |  | Female | 72 | 73.4 | 98.1 | (76.7-123.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

28

# Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 6.4 | 108.8 | (43.6-224.3) |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 3 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 4.0 | nc | (nc-nc) |
| Female | 35 | 28.6 | 122.6 | (85.4-170.5) |  | Female | 3 | 3.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 7.5 | 92.8 | (37.2-191.3) |  |  |  |  |  |  |
| Female | 6 | 7.7 | 77.4 | (28.3-168.5) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 1.8 | 335.0 | (122.3-729.1) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 21 | 24.0 | 87.5 | (54.2-133.8) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 3.9 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 4 | 5.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 9 | 6.3 | 142.8 | (65.2-271.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 11.8 | 118.4 | (64.7-198.7) |  | Male | 83 | 90.7 | 91.5 | (72.9-113.4) |
| Female | 15 | 12.9 | 116.0 | (64.9-191.4) |  | Female | 104 | 95.6 | 108.8 | (88.9-131.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

29

# Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 87 | 70.8 | 122.9 | (98.5-151.6) |  | Male | 65 | 42.5 | 152.8 | (117.9-194.8) |
| Female | 26 | 24.3 | 107.0 | (69.9-156.8) |  | Female | 50 | 30.8 | 162.4 | (120.5-214.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 11.1 | 99.3 | (49.5-177.6) |  | Male | 11 | 12.9 | 85.6 | (42.7-153.1) |
| Female | 9 | 9.5 | 95.2 | (43.5-180.8) |  | Female | 13 | 10.2 | 127.2 | (67.7-217.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 2.1 | nc | (nc-nc) |  | Male | 39 | 37.4 | 104.2 | (74.1-142.5) |
| Female | 298 | 242.4 | 122.9 | (109.4-137.7) |  | Female | 40 | 31.2 | 128.3 | (91.7-174.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 25 | 28.5 | 87.6 | (56.7-129.3) |
| Female | 9 | 7.5 | 119.5 | (54.5-226.9) |  | Female | 14 | 12.8 | 109.2 | (59.6-183.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 63 | 73.9 | 85.2 | (65.5-109.0) |  |  |  |  |  |  |
| Female | 68 | 71.9 | 94.6 | (73.5-119.9) |  | Female | 22 | 22.4 | 98.3 | (61.6-148.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 19 | 17.9 | 105.9 | (63.7-165.4) |  | Male | 27 | 23.4 | 115.5 | (76.1-168.0) |
| Female | 3 | 4.7 | nc | (nc-nc) |  | Female | 26 | 23.6 | 110.0 | (71.8-161.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 4.1 | nc | (nc-nc) |  | Male | 295 | 235.3 | 125.4 | (111.5-140.5) |
| Female | 2 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 30 | 34.2 | 87.6 | (59.1-125.1) |  | Male | 17 | 15.9 | 106.9 | (62.3-171.2) |
| Female | 19 | 19.9 | 95.3 | (57.4-148.8) |  | Female | 8 | 9.1 | 88.3 | (38.0-174.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 9.8 | 101.9 | (48.8-187.4) |  | Male | 9 | 5.9 | 151.7 | (69.2-288.0) |
| Female | 2 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 34 | 25.9 | 131.3 | (90.9-183.5) |  | Male | 12 | 14.1 | 85.2 | (44.0-148.8) |
| Female | 26 | 18.1 | 143.6 | (93.8-210.4) |  | Female | 25 | 39.1 | 64.0 | (41.4-94.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 22 | 21.9 | 100.6 | (63.0-152.4) |  |  |  |  |  |  |
| Female | 8 | 7.2 | 111.7 | (48.1-220.0) |  | Female | 52 | 56.5 | 92.0 | (68.7-120.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 91 | 126.3 | 72.1 | (58.0-88.5) |  | Male | 959 | 883.2 | 108.6 | (101.8-115.7) |
| Female | 126 | 125.9 | 100.1 | (83.3-119.1) |  | Female | 918 | 842.3 | 109.0 | (102.1-116.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

30

# Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 5.6 | 106.7 | (39.0-232.2) |  | Male | 3 | 3.8 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 14 | 21.5 | 65.3 | (35.6-109.5) |  | Female | 0 | 2.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 6.4 | 124.9 | (53.8-246.0) |  |  |  |  |  |  |
| Female | 5 | 5.9 | 84.5 | (27.2-197.2) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 24 | 21.6 | 111.3 | (71.3-165.6) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 3.2 | 155.1 | (50.0-361.8) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 2 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 3 | 1.6 | nc | (nc-nc) |  | Female | 1 | 4.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 7 | 4.8 | 145.1 | (58.1-299.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 10.3 | 116.4 | (60.1-203.4) |  | Male | 77 | 78.1 | 98.6 | (77.8-123.2) |
| Female | 7 | 9.6 | 73.0 | (29.3-150.5) |  | Female | 58 | 71.7 | 80.9 | (61.4-104.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

31

# Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.5 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.4 | nc | (nc-nc) |
| Female | 9 | 8.6 | 104.4 | (47.6-198.2) |  | Female | 2 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 3 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 6 | 10.0 | 59.7 | (21.8-130.0) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 5 | 2.1 | 242.9 | (78.3-566.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 4.7 | 106.2 | (34.2-247.9) |  | Male | 25 | 34.5 | 72.4 | (46.8-106.9) |
| Female | 2 | 4.0 | nc | (nc-nc) |  | Female | 24 | 28.2 | 85.1 | (54.5-126.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

32

# Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 21.3 | 103.5 | (64.8-156.7) |  | Male | 18 | 12.5 | 143.6 | (85.1-226.9) |
| Female | 5 | 6.0 | 82.9 | (26.7-193.4) |  | Female | 3 | 8.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 2 | 3.8 | nc | (nc-nc) |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 11 | 11.2 | 98.6 | (49.2-176.5) |
| Female | 58 | 62.2 | 93.2 | (70.8-120.5) |  | Female | 7 | 7.8 | 89.4 | (35.8-184.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 8.2 | 85.0 | (34.0-175.1) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 22.3 | 112.0 | (72.5-165.4) |  |  |  |  |  |  |
| Female | 20 | 18.3 | 109.3 | (66.8-168.9) |  | Female | 1 | 5.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  | Male | 10 | 6.9 | 144.5 | (69.2-265.7) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 7 | 5.9 | 118.5 | (47.5-244.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 60 | 64.9 | 92.4 | (70.5-118.9) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 9.8 | 81.3 | (35.0-160.2) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 3 | 5.0 | nc | (nc-nc) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 7.9 | 89.0 | (35.6-183.3) |  | Male | 4 | 4.1 | nc | (nc-nc) |
| Female | 5 | 4.7 | 107.1 | (34.5-250.0) |  | Female | 11 | 10.7 | 102.8 | (51.2-183.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 6.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 11 | 14.0 | 78.7 | (39.2-140.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 36.7 | 65.4 | (41.9-97.4) |  | Male | 233 | 256.5 | 90.8 | (79.5-103.3) |
| Female | 30 | 30.8 | 97.5 | (65.8-139.2) |  | Female | 187 | 213.7 | 87.5 | (75.4-101.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

33

# Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 12.9 | 69.8 | (31.9-132.5) |  | Male | 9 | 9.2 | 98.2 | (44.8-186.4) |
| Female | 5 | 4.6 | 107.6 | (34.7-251.2) |  | Female | 6 | 7.7 | 77.8 | (28.4-169.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 2.8 | 210.9 | (77.0-459.1) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 13 | 8.1 | 161.0 | (85.6-275.3) |
| Female | 54 | 60.3 | 89.5 | (67.2-116.8) |  | Female | 7 | 6.7 | 104.3 | (41.8-214.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 7.1 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 7 | 2.9 | 240.2 | (96.2-494.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 15.4 | 90.9 | (49.6-152.5) |  |  |  |  |  |  |
| Female | 16 | 14.6 | 109.4 | (62.5-177.7) |  | Female | 4 | 5.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 3.8 | nc | (nc-nc) |  | Male | 2 | 4.6 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 3 | 4.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 51 | 52.6 | 96.9 | (72.1-127.4) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 8.1 | 62.0 | (20.0-144.6) |  | Male | 6 | 3.2 | 187.9 | (68.6-409.0) |
| Female | 3 | 4.5 | nc | (nc-nc) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 5.5 | 108.9 | (39.8-237.0) |  | Male | 1 | 4.0 | nc | (nc-nc) |
| Female | 2 | 4.0 | nc | (nc-nc) |  | Female | 8 | 12.2 | 65.7 | (28.3-129.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 5.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 16 | 13.8 | 116.0 | (66.2-188.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 24.1 | 70.6 | (41.1-113.1) |  | Male | 167 | 188.6 | 88.6 | (75.6-103.1) |
| Female | 18 | 25.3 | 71.3 | (42.2-112.7) |  | Female | 173 | 193.3 | 89.5 | (76.7-103.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

34

# Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 15.1 | 72.9 | (36.4-130.5) |  | Male | 5 | 10.5 | 47.7 | (15.4-111.4) |
| Female | 7 | 5.5 | 128.0 | (51.3-263.8) |  | Female | 11 | 8.7 | 126.9 | (63.3-227.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 3.2 | 187.7 | (68.5-408.5) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 15 | 9.2 | 162.4 | (90.8-267.8) |
| Female | 76 | 66.8 | 113.8 | (89.6-142.4) |  | Female | 15 | 7.7 | 194.9 | (109.0-321.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 7.7 | 90.6 | (36.3-186.7) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 17.5 | 68.7 | (35.5-120.0) |  |  |  |  |  |  |
| Female | 17 | 16.9 | 100.4 | (58.5-160.8) |  | Female | 2 | 5.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 4.3 | 140.6 | (51.4-306.1) |  | Male | 6 | 5.3 | 114.0 | (41.6-248.1) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 5 | 5.3 | 94.8 | (30.6-221.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 65 | 57.7 | 112.7 | (87.0-143.7) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 9.0 | 88.5 | (38.1-174.3) |  | Male | 5 | 3.7 | 136.8 | (44.1-319.2) |
| Female | 5 | 5.1 | 97.2 | (31.3-226.9) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 6.3 | 110.9 | (44.4-228.6) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 3 | 4.6 | nc | (nc-nc) |  | Female | 13 | 13.4 | 97.0 | (51.6-165.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 5.6 | 107.4 | (39.2-233.8) |  |  |  |  |  |  |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 16 | 15.0 | 106.7 | (61.0-173.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 27.9 | 121.8 | (84.3-170.2) |  | Male | 222 | 212.8 | 104.3 | (91.0-119.0) |
| Female | 21 | 29.6 | 71.0 | (43.9-108.5) |  | Female | 220 | 218.6 | 100.6 | (87.8-114.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

35

# Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 26 | 28.9 | 89.9 | (58.7-131.8) |  | Male | 15 | 18.2 | 82.6 | (46.2-136.2) |
| Female | 5 | 10.6 | 47.4 | (15.3-110.5) |  | Female | 9 | 14.8 | 61.0 | (27.8-115.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 5.1 | 97.3 | (31.4-227.1) |  | Male | 6 | 5.4 | 112.0 | (40.9-243.8) |
| Female | 6 | 4.6 | 130.7 | (47.7-284.5) |  | Female | 5 | 4.5 | 111.6 | (36.0-260.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 17 | 16.0 | 106.0 | (61.7-169.7) |
| Female | 135 | 113.1 | 119.4 | (100.1-141.3) |  | Female | 9 | 14.0 | 64.1 | (29.2-121.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 12.4 | nc | (nc-nc) |
| Female | 1 | 4.0 | nc | (nc-nc) |  | Female | 4 | 5.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 31.3 | 70.3 | (44.0-106.4) |  |  |  |  |  |  |
| Female | 27 | 32.3 | 83.6 | (55.1-121.6) |  | Female | 11 | 10.3 | 106.7 | (53.2-190.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 7.5 | 67.1 | (21.6-156.6) |  | Male | 9 | 9.7 | 92.9 | (42.4-176.4) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 9 | 10.3 | 87.1 | (39.8-165.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 88 | 97.8 | 90.0 | (72.2-110.9) |
| Female | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 14.9 | 60.5 | (27.6-114.8) |  | Male | 4 | 6.6 | nc | (nc-nc) |
| Female | 4 | 9.0 | nc | (nc-nc) |  | Female | 5 | 4.1 | 123.0 | (39.6-287.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 4.1 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 11.2 | nc | (nc-nc) |  | Male | 9 | 6.6 | 136.5 | (62.3-259.1) |
| Female | 4 | 8.4 | nc | (nc-nc) |  | Female | 20 | 20.8 | 96.1 | (58.7-148.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 9.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 24 | 25.6 | 93.9 | (60.1-139.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 31 | 51.6 | 60.1 | (40.8-85.3) |  | Male | 288 | 371.8 | 77.5 | (68.8-86.9) |
| Female | 41 | 54.1 | 75.7 | (54.3-102.7) |  | Female | 350 | 385.7 | 90.8 | (81.5-100.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

36

# Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 5.1 | nc | (nc-nc) |  | Male | 5 | 3.8 | 131.5 | (42.4-306.9) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 4 | 3.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 29 | 23.6 | 123.1 | (82.4-176.8) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 6.3 | 95.7 | (34.9-208.3) |  |  |  |  |  |  |
| Female | 7 | 5.3 | 131.1 | (52.5-270.1) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 19 | 21.5 | 88.5 | (53.2-138.2) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 3.4 | 146.4 | (47.2-341.7) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 4 | 1.7 | nc | (nc-nc) |
| Female | 4 | 1.5 | nc | (nc-nc) |  | Female | 6 | 5.1 | 116.9 | (42.7-254.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 5 | 5.2 | 96.4 | (31.1-224.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 9.7 | 92.4 | (42.2-175.4) |  | Male | 75 | 77.3 | 97.0 | (76.3-121.6) |
| Female | 7 | 9.2 | 76.5 | (30.6-157.6) |  | Female | 86 | 73.5 | 117.0 | (93.6-144.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

37

# Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  | Male | 5 | 2.5 | 201.8 | (65.0-471.0) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 16 | 14.4 | 110.8 | (63.3-180.0) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 3.9 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 4 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 12 | 14.3 | 83.9 | (43.3-146.5) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 5 | 3.3 | 150.7 | (48.6-351.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 7.2 | 153.3 | (76.4-274.3) |  | Male | 59 | 51.7 | 114.1 | (86.9-147.2) |
| Female | 5 | 7.0 | 71.0 | (22.9-165.7) |  | Female | 44 | 48.3 | 91.0 | (66.1-122.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

38

# Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 6 | 1.3 | 447.5 | (163.4-974.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 1.8 | nc | (nc-nc) |
| Female | 10 | 10.7 | 93.4 | (44.7-171.7) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 3.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 3.0 | 169.2 | (54.5-394.9) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 16 | 11.4 | 140.4 | (80.2-228.0) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 5.8 | 86.2 | (27.8-201.2) |  | Male | 42 | 41.9 | 100.4 | (72.3-135.7) |
| Female | 4 | 5.3 | nc | (nc-nc) |  | Female | 38 | 36.1 | 105.2 | (74.4-144.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

39

# Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 54 | 43.4 | 124.3 | (93.4-162.2) |  | Male | 39 | 27.8 | 140.2 | (99.7-191.7) |
| Female | 23 | 16.5 | 139.2 | (88.2-208.9) |  | Female | 34 | 23.1 | 147.0 | (101.8-205.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 7.9 | 150.9 | (77.9-263.7) |  | Male | 9 | 8.2 | 110.3 | (50.3-209.3) |
| Female | 7 | 7.1 | 98.3 | (39.4-202.6) |  | Female | 5 | 7.0 | 71.6 | (23.1-167.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 29 | 24.6 | 117.7 | (78.8-169.0) |
| Female | 177 | 172.9 | 102.3 | (87.8-118.6) |  | Female | 22 | 21.8 | 100.8 | (63.1-152.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 27 | 19.5 | 138.4 | (91.2-201.4) |
| Female | 3 | 6.0 | nc | (nc-nc) |  | Female | 13 | 9.0 | 143.8 | (76.5-246.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 32 | 47.6 | 67.2 | (46.0-94.9) |  |  |  |  |  |  |
| Female | 53 | 50.6 | 104.8 | (78.5-137.1) |  | Female | 17 | 16.0 | 106.2 | (61.8-170.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 11.4 | 104.9 | (54.1-183.2) |  | Male | 14 | 14.7 | 95.4 | (52.1-160.0) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 13 | 16.2 | 80.3 | (42.7-137.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  | Male | 170 | 151.6 | 112.1 | (95.9-130.3) |
| Female | 1 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 23 | 22.9 | 100.4 | (63.6-150.7) |  | Male | 5 | 10.1 | 49.6 | (16.0-115.7) |
| Female | 15 | 13.9 | 107.9 | (60.4-178.0) |  | Female | 4 | 6.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 6.3 | 95.0 | (34.7-206.9) |  | Male | 10 | 5.7 | 175.3 | (83.9-322.5) |
| Female | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 22 | 17.1 | 128.3 | (80.4-194.3) |  | Male | 11 | 10.5 | 104.8 | (52.3-187.6) |
| Female | 13 | 13.1 | 98.9 | (52.6-169.1) |  | Female | 35 | 32.3 | 108.2 | (75.4-150.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 14.5 | 89.5 | (47.6-153.0) |  |  |  |  |  |  |
| Female | 13 | 4.9 | 264.9 | (140.9-452.9) |  | Female | 39 | 39.3 | 99.2 | (70.5-135.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 87 | 77.8 | 111.8 | (89.6-138.0) |  | Male | 633 | 571.0 | 110.9 | (102.4-119.8) |
| Female | 97 | 83.7 | 115.8 | (93.9-141.3) |  | Female | 662 | 597.0 | 110.9 | (102.6-119.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

40

# Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 53 | 38.2 | 138.9 | (104.0-181.6) |  | Male | 35 | 26.6 | 131.7 | (91.7-183.1) |
| Female | 18 | 13.2 | 136.2 | (80.7-215.2) |  | Female | 22 | 20.9 | 105.2 | (65.9-159.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 8.1 | 86.4 | (34.6-178.1) |  | Male | 12 | 7.7 | 156.8 | (80.9-273.9) |
| Female | 6 | 6.4 | 93.1 | (34.0-202.7) |  | Female | 5 | 5.8 | 86.3 | (27.8-201.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 20 | 23.4 | 85.6 | (52.2-132.1) |
| Female | 151 | 161.4 | 93.6 | (79.2-109.7) |  | Female | 20 | 18.7 | 107.2 | (65.4-165.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 19.7 | 91.1 | (54.0-144.1) |
| Female | 3 | 5.9 | nc | (nc-nc) |  | Female | 9 | 7.9 | 113.8 | (51.9-216.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 28 | 44.3 | 63.3 | (42.0-91.4) |  |  |  |  |  |  |
| Female | 55 | 40.7 | 135.2 | (101.8-175.9) |  | Female | 18 | 14.5 | 124.5 | (73.8-196.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 11.0 | 100.2 | (50.0-179.4) |  | Male | 17 | 13.5 | 126.4 | (73.6-202.3) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 10 | 12.8 | 78.3 | (37.5-144.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  | Male | 140 | 151.3 | 92.5 | (77.8-109.2) |
| Female | 1 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 23.1 | 116.7 | (76.9-169.8) |  | Male | 9 | 9.3 | 97.0 | (44.3-184.1) |
| Female | 11 | 12.5 | 88.3 | (44.0-158.1) |  | Female | 6 | 5.0 | 119.7 | (43.7-260.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 6.1 | nc | (nc-nc) |  | Male | 7 | 6.3 | 111.0 | (44.5-228.6) |
| Female | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 23 | 15.9 | 144.6 | (91.6-216.9) |  | Male | 15 | 11.3 | 132.9 | (74.3-219.2) |
| Female | 20 | 11.1 | 180.8 | (110.4-279.2) |  | Female | 31 | 32.0 | 96.8 | (65.7-137.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 14.2 | 77.6 | (38.7-138.9) |  |  |  |  |  |  |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 29 | 36.8 | 78.9 | (52.8-113.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 86 | 71.5 | 120.4 | (96.3-148.6) |  | Male | 573 | 545.8 | 105.0 | (96.6-113.9) |
| Female | 98 | 72.2 | 135.8 | (110.2-165.5) |  | Female | 556 | 528.7 | 105.2 | (96.6-114.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

41

# Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 8.0 | 99.6 | (42.9-196.2) |  | Male | 4 | 5.6 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 5 | 4.8 | 104.7 | (33.8-244.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.0 | 100.5 | (32.4-234.6) |
| Female | 29 | 36.2 | 80.1 | (53.7-115.1) |  | Female | 5 | 4.3 | 117.3 | (37.8-273.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 9.5 | 63.3 | (23.1-137.7) |  |  |  |  |  |  |
| Female | 6 | 9.6 | 62.3 | (22.7-135.6) |  | Female | 5 | 3.3 | 153.1 | (49.3-357.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 2.3 | 352.2 | (151.6-694.0) |  | Male | 0 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 25 | 30.7 | 81.5 | (52.7-120.3) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.8 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 5 | 2.8 | 178.5 | (57.5-416.5) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 5 | 2.6 | 193.2 | (62.3-450.8) |  | Female | 3 | 7.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 11 | 8.1 | 136.0 | (67.8-243.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 14.7 | 169.7 | (109.8-250.6) |  | Male | 119 | 113.9 | 104.5 | (86.5-125.0) |
| Female | 16 | 16.1 | 99.6 | (56.9-161.7) |  | Female | 123 | 120.0 | 102.5 | (85.2-122.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

42

# Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 3 | 5.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 7 | 6.7 | 104.6 | (41.9-215.5) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 18 | 23.2 | 77.5 | (45.9-122.5) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 17 | 17.5 | 97.0 | (56.5-155.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

43

# Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 4.2 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 23 | 19.6 | 117.1 | (74.2-175.7) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 5.2 | 96.0 | (30.9-224.0) |  |  |  |  |  |  |
| Female | 2 | 4.5 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 24 | 19.0 | 126.5 | (81.0-188.2) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 11 | 4.4 | 248.4 | (123.8-444.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 8.1 | 61.6 | (19.8-143.7) |  | Male | 61 | 65.0 | 93.8 | (71.7-120.5) |
| Female | 5 | 7.6 | 66.1 | (21.3-154.2) |  | Female | 57 | 60.8 | 93.8 | (71.0-121.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

44

# Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 350 | 452.6 | 77.3 | (69.4-85.9) |  | Male | 252 | 313.5 | 80.4 | (70.8-91.0) |
| Female | 155 | 178.6 | 86.8 | (73.7-101.6) |  | Female | 202 | 296.3 | 68.2 | (59.1-78.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 76 | 100.7 | 75.5 | (59.5-94.5) |  | Male | 102 | 87.2 | 117.0 | (95.4-142.0) |
| Female | 84 | 90.8 | 92.5 | (73.8-114.5) |  | Female | 115 | 76.3 | 150.7 | (124.4-180.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 10 | 14.3 | 69.8 | (33.4-128.3) |  | Male | 297 | 279.5 | 106.3 | (94.5-119.1) |
| Female | 1823 | 1991.0 | 91.6 | (87.4-95.9) |  | Female | 238 | 248.9 | 95.6 | (83.8-108.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 251 | 217.8 | 115.3 | (101.4-130.4) |
| Female | 91 | 80.5 | 113.0 | (91.0-138.8) |  | Female | 113 | 102.6 | 110.1 | (90.8-132.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 573 | 511.1 | 112.1 | (103.1-121.7) |  |  |  |  |  |  |
| Female | 587 | 550.9 | 106.6 | (98.1-115.5) |  | Female | 185 | 187.4 | 98.7 | (85.0-114.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 116 | 122.2 | 94.9 | (78.4-113.8) |  | Male | 145 | 155.2 | 93.5 | (78.9-110.0) |
| Female | 37 | 34.4 | 107.7 | (75.8-148.5) |  | Female | 185 | 174.2 | 106.2 | (91.5-122.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 55 | 57.7 | 95.3 | (71.8-124.0) |  | Male | 1953 | 1633.1 | 119.6 | (114.3-125.0) |
| Female | 59 | 53.2 | 110.8 | (84.4-143.0) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 232 | 258.3 | 89.8 | (78.6-102.2) |  | Male | 148 | 107.5 | 137.6 | (116.4-161.7) |
| Female | 181 | 159.3 | 113.6 | (97.7-131.5) |  | Female | 104 | 69.5 | 149.7 | (122.3-181.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 88 | 67.8 | 129.7 | (104.0-159.8) |  | Male | 93 | 112.7 | 82.5 | (66.6-101.1) |
| Female | 23 | 24.0 | 95.7 | (60.7-143.6) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 146 | 196.8 | 74.2 | (62.7-87.3) |  | Male | 152 | 138.1 | 110.0 | (93.2-129.0) |
| Female | 117 | 155.5 | 75.3 | (62.2-90.2) |  | Female | 506 | 464.2 | 109.0 | (99.7-118.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 272 | 157.0 | 173.3 | (153.3-195.1) |  |  |  |  |  |  |
| Female | 96 | 54.5 | 176.1 | (142.6-215.1) |  | Female | 446 | 448.7 | 99.4 | (90.4-109.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 903 | 818.4 | 110.3 | (103.3-117.8) |  | Male | 6719 | 6287.1 | 106.9 | (104.3-109.5) |
| Female | 843 | 928.6 | 90.8 | (84.8-97.1) |  | Female | 6722 | 6913.6 | 97.2 | (94.9-99.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

45

# Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 34 | 27.1 | 125.4 | (86.8-175.3) |  | Male | 22 | 16.8 | 131.2 | (82.2-198.7) |
| Female | 11 | 9.8 | 112.0 | (55.8-200.4) |  | Female | 16 | 12.4 | 128.8 | (73.6-209.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.6 | 131.3 | (47.9-285.7) |  | Male | 7 | 5.0 | 139.9 | (56.0-288.2) |
| Female | 6 | 3.8 | 156.4 | (57.1-340.3) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 15 | 14.7 | 101.7 | (56.9-167.8) |
| Female | 89 | 96.9 | 91.8 | (73.7-113.0) |  | Female | 9 | 12.6 | 71.7 | (32.7-136.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 11.5 | 122.2 | (66.7-205.0) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 5 | 5.1 | 97.1 | (31.3-226.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 23 | 28.7 | 80.2 | (50.8-120.4) |  |  |  |  |  |  |
| Female | 20 | 29.1 | 68.8 | (42.0-106.2) |  | Female | 14 | 9.0 | 156.0 | (85.2-261.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 7.1 | 113.3 | (48.8-223.3) |  | Male | 7 | 9.1 | 77.2 | (30.9-159.0) |
| Female | 6 | 1.9 | 317.9 | (116.1-691.9) |  | Female | 11 | 9.6 | 114.6 | (57.1-205.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 102 | 93.8 | 108.7 | (88.6-131.9) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 13.7 | 95.0 | (50.6-162.5) |  | Male | 5 | 6.2 | 81.2 | (26.2-189.5) |
| Female | 7 | 8.0 | 87.4 | (35.0-180.2) |  | Female | 5 | 3.7 | 136.1 | (43.9-317.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 3.9 | 180.6 | (72.4-372.1) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 4 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 10.3 | 87.7 | (40.0-166.5) |  | Male | 1 | 5.9 | nc | (nc-nc) |
| Female | 7 | 7.4 | 95.2 | (38.1-196.1) |  | Female | 17 | 15.7 | 108.1 | (62.9-173.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 8.7 | 57.6 | (18.6-134.3) |  |  |  |  |  |  |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 22 | 22.6 | 97.4 | (61.0-147.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 56 | 49.1 | 114.1 | (86.2-148.1) |  | Male | 365 | 348.4 | 104.8 | (94.3-116.1) |
| Female | 63 | 50.5 | 124.9 | (95.9-159.8) |  | Female | 341 | 338.6 | 100.7 | (90.3-112.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

46

# Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 4.2 | nc | (nc-nc) |  | Male | 5 | 3.2 | 157.7 | (50.8-368.0) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 5 | 2.4 | 204.7 | (66.0-477.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 22 | 19.8 | 111.1 | (69.6-168.3) |  | Female | 4 | 2.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 5.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 4.4 | 159.6 | (63.9-328.9) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 22 | 18.4 | 119.4 | (74.8-180.8) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 3 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 3 | 1.4 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 6 | 4.5 | 134.0 | (48.9-291.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 8.1 | 61.7 | (19.9-144.1) |  | Male | 58 | 65.2 | 88.9 | (67.5-115.0) |
| Female | 9 | 7.5 | 119.3 | (54.4-226.4) |  | Female | 74 | 60.6 | 122.0 | (95.8-153.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

47

# Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 9.2 | 76.3 | (30.6-157.2) |  | Male | 18 | 6.1 | 295.1 | (174.8-466.5) |
| Female | 1 | 2.8 | nc | (nc-nc) |  | Female | 12 | 4.3 | 276.4 | (142.6-482.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 4 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 1 | 5.4 | nc | (nc-nc) |
| Female | 45 | 35.6 | 126.5 | (92.3-169.3) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 10.5 | 47.7 | (15.4-111.3) |  |  |  |  |  |  |
| Female | 6 | 8.7 | 68.7 | (25.1-149.5) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.6 | nc | (nc-nc) |  | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 50 | 36.0 | 138.9 | (103.1-183.1) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 5.3 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 3.6 | 192.6 | (77.2-396.8) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 7 | 6.5 | 107.0 | (42.9-220.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 6 | 8.2 | 73.5 | (26.8-160.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 17.1 | 35.0 | (12.8-76.3) |  | Male | 124 | 127.8 | 97.0 | (80.7-115.7) |
| Female | 7 | 15.3 | 45.8 | (18.4-94.4) |  | Female | 114 | 113.6 | 100.4 | (82.8-120.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

48

# Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 4.8 | 124.6 | (45.5-271.2) |  | Male | 4 | 3.2 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 8 | 2.5 | 316.6 | (136.3-623.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 3 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 27 | 20.0 | 135.2 | (89.1-196.7) |  | Female | 0 | 2.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 5.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 8 | 5.2 | 153.6 | (66.1-302.7) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 13 | 18.6 | 69.8 | (37.1-119.3) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 4 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 3 | 3.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 4.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 8.9 | nc | (nc-nc) |  | Male | 58 | 67.1 | 86.5 | (65.6-111.8) |
| Female | 6 | 9.1 | 66.3 | (24.2-144.2) |  | Female | 69 | 65.8 | 104.9 | (81.6-132.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

49

# Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 50 | 42.6 | 117.4 | (87.2-154.8) |  | Male | 29 | 26.5 | 109.3 | (73.2-157.0) |
| Female | 23 | 16.8 | 136.7 | (86.6-205.1) |  | Female | 31 | 22.2 | 139.8 | (95.0-198.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 7.4 | 107.5 | (46.3-211.8) |  | Male | 4 | 7.8 | nc | (nc-nc) |
| Female | 7 | 6.9 | 102.0 | (40.9-210.1) |  | Female | 8 | 7.0 | 114.0 | (49.1-224.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 26 | 23.5 | 110.7 | (72.3-162.3) |
| Female | 187 | 168.2 | 111.2 | (95.8-128.3) |  | Female | 21 | 21.7 | 96.8 | (59.9-148.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 17.9 | 100.5 | (59.5-158.8) |
| Female | 8 | 5.7 | 140.5 | (60.5-276.9) |  | Female | 8 | 8.8 | 90.5 | (39.0-178.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 56 | 45.8 | 122.3 | (92.4-158.8) |  |  |  |  |  |  |
| Female | 74 | 50.9 | 145.5 | (114.2-182.6) |  | Female | 13 | 15.5 | 84.1 | (44.7-143.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 10.8 | 120.3 | (64.0-205.7) |  | Male | 13 | 14.1 | 92.0 | (48.9-157.3) |
| Female | 5 | 3.2 | 156.1 | (50.3-364.3) |  | Female | 18 | 16.5 | 109.2 | (64.7-172.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 3.0 | 167.1 | (53.9-390.0) |  | Male | 132 | 140.1 | 94.2 | (78.8-111.7) |
| Female | 5 | 2.7 | 188.1 | (60.6-439.0) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 18 | 21.5 | 83.9 | (49.7-132.5) |  | Male | 10 | 9.7 | 102.9 | (49.3-189.3) |
| Female | 12 | 13.8 | 87.1 | (45.0-152.1) |  | Female | 8 | 6.5 | 124.0 | (53.4-244.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 5.9 | nc | (nc-nc) |  | Male | 3 | 4.9 | nc | (nc-nc) |
| Female | 6 | 2.1 | 287.4 | (105.0-625.6) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 16.4 | 66.9 | (33.4-119.7) |  | Male | 9 | 9.5 | 94.6 | (43.1-179.5) |
| Female | 19 | 13.1 | 145.1 | (87.3-226.6) |  | Female | 35 | 29.8 | 117.4 | (81.7-163.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 16 | 13.4 | 119.3 | (68.1-193.7) |  |  |  |  |  |  |
| Female | 5 | 4.9 | 102.5 | (33.0-239.3) |  | Female | 37 | 37.6 | 98.3 | (69.2-135.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 68 | 75.4 | 90.2 | (70.0-114.3) |  | Male | 536 | 540.7 | 99.1 | (90.9-107.9) |
| Female | 88 | 85.0 | 103.5 | (83.0-127.5) |  | Female | 671 | 587.6 | 114.2 | (105.7-123.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

50

# Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 19.9 | 85.3 | (49.7-136.6) |  | Male | 17 | 11.2 | 151.2 | (88.0-242.2) |
| Female | 8 | 7.2 | 110.4 | (47.5-217.5) |  | Female | 16 | 8.1 | 196.7 | (112.4-319.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 14 | 9.9 | 140.7 | (76.9-236.1) |
| Female | 80 | 64.2 | 124.6 | (98.8-155.1) |  | Female | 12 | 8.8 | 135.6 | (70.0-236.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 7.3 | 109.7 | (47.2-216.1) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 20.1 | 84.6 | (49.3-135.5) |  |  |  |  |  |  |
| Female | 16 | 21.4 | 74.8 | (42.8-121.6) |  | Female | 4 | 6.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.8 | nc | (nc-nc) |  | Male | 6 | 6.5 | 92.9 | (33.9-202.3) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 4 | 7.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 75 | 62.4 | 120.1 | (94.5-150.6) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 8.8 | 79.8 | (32.0-164.4) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 5 | 5.5 | 91.6 | (29.5-213.7) |  | Female | 0 | 2.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.6 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 7.0 | 86.1 | (31.5-187.5) |  | Male | 0 | 3.3 | nc | (nc-nc) |
| Female | 3 | 5.2 | nc | (nc-nc) |  | Female | 8 | 8.9 | 89.9 | (38.7-177.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 15 | 15.2 | 98.9 | (55.3-163.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 34.6 | 83.7 | (56.1-120.3) |  | Male | 237 | 236.3 | 100.3 | (87.9-113.9) |
| Female | 17 | 35.5 | 47.8 | (27.8-76.6) |  | Female | 216 | 232.1 | 93.1 | (81.1-106.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

51

# Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 23.2 | 116.2 | (76.6-169.1) |  | Male | 19 | 16.5 | 115.0 | (69.2-179.5) |
| Female | 12 | 7.5 | 160.4 | (82.8-280.3) |  | Female | 17 | 12.0 | 141.7 | (82.5-226.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.1 | 117.2 | (42.8-255.2) |  | Male | 2 | 4.7 | nc | (nc-nc) |
| Female | 7 | 3.8 | 185.0 | (74.1-381.2) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 10 | 14.6 | 68.4 | (32.7-125.7) |
| Female | 88 | 89.5 | 98.4 | (78.9-121.2) |  | Female | 8 | 10.6 | 75.8 | (32.7-149.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 12.4 | 56.5 | (22.6-116.4) |
| Female | 4 | 3.3 | nc | (nc-nc) |  | Female | 6 | 4.5 | 134.5 | (49.1-292.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 27.4 | 87.5 | (56.1-130.2) |  |  |  |  |  |  |
| Female | 25 | 23.3 | 107.5 | (69.5-158.6) |  | Female | 10 | 8.2 | 122.6 | (58.7-225.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 6.7 | 119.7 | (51.6-235.9) |  | Male | 8 | 8.3 | 96.9 | (41.7-191.0) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 12 | 7.2 | 166.0 | (85.7-289.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 88 | 91.6 | 96.1 | (77.1-118.4) |
| Female | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 14.3 | 76.9 | (38.3-137.5) |  | Male | 4 | 5.7 | nc | (nc-nc) |
| Female | 4 | 6.9 | nc | (nc-nc) |  | Female | 5 | 2.9 | 172.3 | (55.5-402.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.7 | nc | (nc-nc) |  | Male | 1 | 4.5 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 10.0 | 50.2 | (16.2-117.2) |  | Male | 13 | 7.3 | 178.1 | (94.7-304.6) |
| Female | 3 | 6.4 | nc | (nc-nc) |  | Female | 27 | 18.6 | 145.2 | (95.6-211.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 8.8 | 159.5 | (87.1-267.6) |  |  |  |  |  |  |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 15 | 20.2 | 74.4 | (41.6-122.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 55 | 43.1 | 127.6 | (96.1-166.1) |  | Male | 332 | 336.0 | 98.8 | (88.5-110.0) |
| Female | 31 | 39.9 | 77.6 | (52.7-110.2) |  | Female | 299 | 297.3 | 100.6 | (89.5-112.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

52

# Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 4.1 | nc | (nc-nc) |  | Male | 0 | 2.8 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 2.4 | 205.6 | (66.3-479.9) |
| Female | 16 | 16.6 | 96.6 | (55.2-156.9) |  | Female | 4 | 1.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 4.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 4.2 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 11 | 16.4 | 67.1 | (33.4-120.0) |
| Female | 2 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 2 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 3 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 4 | 3.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 6 | 7.7 | 78.0 | (28.5-169.7) |  | Male | 49 | 57.9 | 84.6 | (62.6-111.9) |
| Female | 11 | 7.4 | 148.5 | (74.0-265.8) |  | Female | 51 | 54.1 | 94.3 | (70.2-124.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

53

# Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 77 | 82.9 | 92.9 | (73.3-116.1) |  | Male | 32 | 55.7 | 57.5 | (39.3-81.2) |
| Female | 28 | 31.8 | 88.0 | (58.5-127.3) |  | Female | 28 | 48.5 | 57.7 | (38.3-83.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 12 | 17.3 | 69.3 | (35.8-121.1) |  | Male | 14 | 16.0 | 87.4 | (47.7-146.6) |
| Female | 15 | 15.3 | 98.0 | (54.8-161.6) |  | Female | 14 | 13.6 | 102.6 | (56.0-172.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 43 | 49.4 | 87.1 | (63.0-117.3) |
| Female | 327 | 359.3 | 91.0 | (81.4-101.4) |  | Female | 43 | 43.7 | 98.4 | (71.2-132.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 39 | 39.7 | 98.1 | (69.8-134.2) |
| Female | 25 | 13.4 | 187.2 | (121.1-276.4) |  | Female | 17 | 18.2 | 93.3 | (54.3-149.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 114 | 93.5 | 121.9 | (100.5-146.4) |  |  |  |  |  |  |
| Female | 109 | 97.7 | 111.5 | (91.6-134.5) |  | Female | 40 | 32.9 | 121.6 | (86.9-165.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 22 | 22.6 | 97.5 | (61.1-147.6) |  | Male | 32 | 28.5 | 112.1 | (76.7-158.3) |
| Female | 8 | 6.1 | 130.8 | (56.3-257.7) |  | Female | 37 | 31.0 | 119.5 | (84.1-164.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 7.8 | nc | (nc-nc) |  | Male | 320 | 303.4 | 105.5 | (94.2-117.7) |
| Female | 8 | 6.8 | 117.1 | (50.4-230.7) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 57 | 47.0 | 121.4 | (91.9-157.3) |  | Male | 24 | 19.7 | 122.0 | (78.2-181.6) |
| Female | 26 | 28.5 | 91.3 | (59.7-133.9) |  | Female | 15 | 12.3 | 122.4 | (68.4-201.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 17 | 12.5 | 135.7 | (79.0-217.2) |  | Male | 12 | 13.6 | 88.1 | (45.5-153.8) |
| Female | 6 | 4.4 | 137.5 | (50.2-299.3) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 26 | 34.9 | 74.6 | (48.7-109.3) |  | Male | 31 | 22.7 | 136.8 | (92.9-194.2) |
| Female | 22 | 26.9 | 81.8 | (51.2-123.8) |  | Female | 101 | 72.7 | 138.8 | (113.1-168.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 36 | 29.0 | 124.0 | (86.9-171.7) |  |  |  |  |  |  |
| Female | 16 | 9.8 | 164.0 | (93.7-266.4) |  | Female | 78 | 81.4 | 95.9 | (75.8-119.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 184 | 150.9 | 122.0 | (105.0-140.9) |  | Male | 1187 | 1136.5 | 104.4 | (98.6-110.6) |
| Female | 202 | 166.3 | 121.4 | (105.3-139.4) |  | Female | 1271 | 1216.1 | 104.5 | (98.9-110.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

54

# Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 4.0 | 150.4 | (54.9-327.4) |  | Male | 4 | 2.7 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 2.3 | nc | (nc-nc) |
| Female | 16 | 15.7 | 101.6 | (58.1-165.1) |  | Female | 3 | 1.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 4.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 4.2 | 166.1 | (66.5-342.2) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 14 | 15.8 | 88.7 | (48.5-148.9) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 0 | 2.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 0.4 | nc | (nc-nc) |  | Female | 5 | 3.7 | 136.9 | (44.1-319.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 7.5 | 133.7 | (64.0-245.8) |  | Male | 46 | 55.5 | 82.8 | (60.6-110.5) |
| Female | 8 | 7.7 | 104.5 | (45.0-205.8) |  | Female | 57 | 52.8 | 107.9 | (81.7-139.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

55

# Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 54 | 55.2 | 97.9 | (73.5-127.7) |  | Male | 42 | 35.5 | 118.4 | (85.3-160.0) |
| Female | 14 | 20.9 | 66.9 | (36.5-112.2) |  | Female | 43 | 32.6 | 131.9 | (95.4-177.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 14 | 10.5 | 133.9 | (73.1-224.7) |  | Male | 10 | 10.2 | 97.8 | (46.8-179.8) |
| Female | 10 | 9.9 | 100.6 | (48.2-185.1) |  | Female | 8 | 8.9 | 89.8 | (38.7-176.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 40 | 31.4 | 127.4 | (91.0-173.4) |
| Female | 253 | 223.9 | 113.0 | (99.5-127.8) |  | Female | 35 | 28.5 | 122.9 | (85.6-170.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 24.0 | 87.6 | (54.2-133.9) |
| Female | 1 | 8.7 | nc | (nc-nc) |  | Female | 8 | 11.7 | 68.2 | (29.4-134.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 38 | 59.4 | 63.9 | (45.2-87.8) |  |  |  |  |  |  |
| Female | 44 | 63.9 | 68.8 | (50.0-92.4) |  | Female | 32 | 21.1 | 151.3 | (103.5-213.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 14.3 | 41.9 | (15.3-91.2) |  | Male | 22 | 18.5 | 118.7 | (74.4-179.8) |
| Female | 2 | 4.0 | nc | (nc-nc) |  | Female | 26 | 20.6 | 126.3 | (82.5-185.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 192 | 189.4 | 101.4 | (87.5-116.8) |
| Female | 6 | 5.2 | 114.4 | (41.8-249.0) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 33 | 28.8 | 114.7 | (79.0-161.2) |  | Male | 10 | 12.7 | 78.8 | (37.7-144.9) |
| Female | 18 | 18.1 | 99.5 | (58.9-157.2) |  | Female | 9 | 8.1 | 111.2 | (50.7-211.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 7.8 | nc | (nc-nc) |  | Male | 13 | 9.4 | 138.6 | (73.7-236.9) |
| Female | 0 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 33 | 22.1 | 149.1 | (102.6-209.4) |  | Male | 17 | 13.8 | 123.5 | (71.9-197.7) |
| Female | 26 | 17.5 | 148.6 | (97.0-217.7) |  | Female | 53 | 48.7 | 108.8 | (81.5-142.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 17.7 | 39.5 | (15.8-81.3) |  |  |  |  |  |  |
| Female | 6 | 6.3 | 94.9 | (34.7-206.6) |  | Female | 47 | 51.7 | 90.9 | (66.8-120.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 66 | 98.2 | 67.2 | (52.0-85.5) |  | Male | 674 | 722.3 | 93.3 | (86.4-100.6) |
| Female | 79 | 106.8 | 74.0 | (58.5-92.2) |  | Female | 779 | 782.9 | 99.5 | (92.6-106.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

56

# Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 3 | 1.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.4 | nc | (nc-nc) |
| Female | 12 | 9.7 | 123.7 | (63.9-216.1) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 10 | 9.3 | 107.2 | (51.3-197.1) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 2.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 4.5 | nc | (nc-nc) |  | Male | 26 | 33.0 | 78.8 | (51.4-115.4) |
| Female | 5 | 4.7 | 106.3 | (34.3-248.1) |  | Female | 38 | 32.6 | 116.5 | (82.5-159.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

57

# Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 30 | 30.0 | 100.1 | (67.6-143.0) |  | Male | 15 | 19.0 | 79.1 | (44.2-130.5) |
| Female | 7 | 10.8 | 64.9 | (26.0-133.8) |  | Female | 16 | 14.7 | 108.9 | (62.2-176.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 5.3 | 169.4 | (77.3-321.7) |  | Male | 6 | 5.6 | 107.3 | (39.2-233.5) |
| Female | 2 | 4.5 | nc | (nc-nc) |  | Female | 5 | 4.6 | 109.8 | (35.4-256.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 26 | 16.6 | 156.4 | (102.2-229.2) |
| Female | 123 | 112.5 | 109.3 | (90.9-130.5) |  | Female | 15 | 14.2 | 105.9 | (59.2-174.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 12.8 | 70.0 | (32.0-133.0) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 4 | 5.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 32 | 32.1 | 99.7 | (68.2-140.8) |  |  |  |  |  |  |
| Female | 30 | 32.1 | 93.6 | (63.1-133.6) |  | Female | 7 | 10.3 | 68.2 | (27.3-140.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 7.8 | nc | (nc-nc) |  | Male | 11 | 10.0 | 109.8 | (54.8-196.5) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 13 | 10.4 | 124.6 | (66.3-213.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 99 | 102.1 | 97.0 | (78.8-118.1) |
| Female | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 18 | 15.5 | 116.0 | (68.7-183.3) |  | Male | 5 | 6.9 | 72.9 | (23.5-170.0) |
| Female | 8 | 9.2 | 87.1 | (37.5-171.7) |  | Female | 5 | 4.0 | 124.4 | (40.1-290.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 11.5 | 156.1 | (92.4-246.6) |  | Male | 11 | 6.9 | 159.4 | (79.5-285.2) |
| Female | 7 | 8.4 | 83.2 | (33.3-171.5) |  | Female | 28 | 20.2 | 138.5 | (92.0-200.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 9.6 | 83.1 | (35.8-163.7) |  |  |  |  |  |  |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 31 | 25.7 | 120.7 | (82.0-171.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 47 | 54.4 | 86.5 | (63.5-115.0) |  | Male | 398 | 386.9 | 102.9 | (93.0-113.5) |
| Female | 55 | 56.8 | 96.8 | (72.9-126.0) |  | Female | 399 | 387.5 | 103.0 | (93.1-113.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

58

# Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 43 | 73.3 | 58.7 | (42.4-79.0) |  | Male | 56 | 51.3 | 109.2 | (82.5-141.8) |
| Female | 20 | 27.9 | 71.8 | (43.8-110.9) |  | Female | 41 | 49.6 | 82.7 | (59.4-112.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 17 | 16.6 | 102.6 | (59.7-164.3) |  | Male | 16 | 13.9 | 115.1 | (65.8-187.0) |
| Female | 14 | 14.8 | 94.8 | (51.8-159.1) |  | Female | 11 | 12.0 | 91.6 | (45.7-163.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 37 | 45.6 | 81.2 | (57.1-111.9) |
| Female | 300 | 313.8 | 95.6 | (85.1-107.0) |  | Female | 32 | 39.7 | 80.6 | (55.1-113.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 33 | 34.4 | 96.0 | (66.0-134.8) |
| Female | 9 | 13.6 | 66.1 | (30.2-125.5) |  | Female | 13 | 16.3 | 79.7 | (42.4-136.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 77 | 81.5 | 94.5 | (74.6-118.2) |  |  |  |  |  |  |
| Female | 76 | 85.4 | 89.0 | (70.1-111.4) |  | Female | 18 | 30.1 | 59.9 | (35.5-94.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 19.5 | 46.1 | (21.1-87.6) |  | Male | 29 | 25.0 | 116.0 | (77.7-166.6) |
| Female | 6 | 5.4 | 111.4 | (40.7-242.4) |  | Female | 25 | 27.2 | 92.0 | (59.6-135.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 7 | 10.7 | 65.4 | (26.2-134.8) |  | Male | 243 | 260.8 | 93.2 | (81.8-105.6) |
| Female | 6 | 9.5 | 62.9 | (23.0-136.8) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 26 | 41.2 | 63.1 | (41.2-92.5) |  | Male | 12 | 17.3 | 69.4 | (35.8-121.2) |
| Female | 11 | 25.2 | 43.7 | (21.8-78.1) |  | Female | 9 | 10.8 | 83.6 | (38.1-158.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 10.8 | 74.1 | (31.9-146.0) |  | Male | 24 | 22.4 | 107.1 | (68.6-159.4) |
| Female | 2 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 32.0 | 62.4 | (38.1-96.4) |  | Male | 29 | 23.3 | 124.4 | (83.3-178.6) |
| Female | 20 | 24.6 | 81.3 | (49.6-125.6) |  | Female | 79 | 79.8 | 99.0 | (78.4-123.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 20 | 24.7 | 80.9 | (49.4-124.9) |  |  |  |  |  |  |
| Female | 11 | 8.6 | 127.5 | (63.5-228.1) |  | Female | 70 | 72.3 | 96.9 | (75.5-122.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 109 | 131.7 | 82.8 | (68.0-99.8) |  | Male | 876 | 1017.3 | 86.1 | (80.5-92.0) |
| Female | 107 | 146.2 | 73.2 | (60.0-88.5) |  | Female | 952 | 1101.8 | 86.4 | (81.0-92.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

59

# Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 26.5 | 79.1 | (49.0-120.9) |  | Male | 18 | 16.4 | 109.8 | (65.0-173.5) |
| Female | 9 | 10.1 | 88.7 | (40.5-168.4) |  | Female | 14 | 13.4 | 104.8 | (57.2-175.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 4.6 | nc | (nc-nc) |  | Male | 6 | 4.9 | 123.1 | (45.0-268.0) |
| Female | 5 | 4.1 | 120.9 | (39.0-282.2) |  | Female | 8 | 4.2 | 189.2 | (81.5-372.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 12 | 14.6 | 82.3 | (42.5-143.8) |
| Female | 95 | 101.6 | 93.5 | (75.7-114.4) |  | Female | 16 | 13.1 | 122.4 | (69.9-198.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 11.2 | 89.3 | (42.7-164.2) |
| Female | 2 | 3.4 | nc | (nc-nc) |  | Female | 10 | 5.4 | 186.9 | (89.5-343.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 28.5 | 108.6 | (73.8-154.2) |  |  |  |  |  |  |
| Female | 29 | 31.1 | 93.3 | (62.5-134.0) |  | Female | 7 | 9.4 | 74.8 | (29.9-154.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 6.8 | 88.7 | (32.4-193.1) |  | Male | 10 | 8.8 | 113.2 | (54.2-208.2) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 9 | 10.0 | 89.8 | (41.0-170.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 81 | 88.0 | 92.1 | (73.1-114.4) |
| Female | 2 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 13.3 | 82.7 | (41.2-148.0) |  | Male | 2 | 6.1 | nc | (nc-nc) |
| Female | 4 | 8.2 | nc | (nc-nc) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 10.2 | 146.8 | (82.1-242.1) |  | Male | 10 | 5.8 | 171.6 | (82.2-315.7) |
| Female | 6 | 7.9 | 75.7 | (27.6-164.7) |  | Female | 28 | 17.9 | 156.0 | (103.7-225.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 8.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.9 | nc | (nc-nc) |  | Female | 26 | 22.7 | 114.4 | (74.7-167.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 40 | 46.7 | 85.6 | (61.1-116.6) |  | Male | 322 | 336.7 | 95.6 | (85.5-106.7) |
| Female | 61 | 50.1 | 121.9 | (93.2-156.6) |  | Female | 368 | 354.0 | 104.0 | (93.6-115.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

60